SULLIVAN LARA (Chief Executive Officer) sold 1.1% of their position (27.92K shares) of PYXIS ONCOLOGY, INC. on the open market
Open‑market sale worth $63.3K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 9/13/2023ACC: 0001209191-23-049366
DirectorOfficer· Chief Executive Officer
Since Oct 2021
-212.66K
Net shares
Net seller
$456.8K
Total sold
3
Open market trades
0B · 3S
4
Total transactions
212.66K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−20K
Price / share
$2.27
Trade value
$45.41K
% of position
0.8%
9/11/2023
2.63M→2.61M
Common Stock
Direct
Shares
−4.92K
Price / share
$2.25
Trade value
$11.07K
% of position
0.2%
9/12/2023
2.61M→2.60M
Common Stock
Direct
Shares
−3K
Price / share
$2.27
Trade value
$6.82K
% of position
0.1%
9/13/2023
2.60M→2.60M
Common Stock
Direct
Shares
−184.74K
Price / share
$2.13
Trade value
$393.50K
% of position
7.1%
9/13/2023
2.60M→2.41M
Total
Net shares
−212.66K
Net value
-$456.80K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/11/2023 | S · Sale | −20K | $2.27 | $45.41K | 0.8% | 2.63M | 2.61M |
| Common Stock Direct | 9/12/2023 | S · Sale | −4.92K | $2.25 | $11.07K | 0.2% | 2.61M | 2.60M |
| Common Stock Direct | 9/13/2023 | S · Sale | −3K | $2.27 | $6.82K | 0.1% | 2.60M | 2.60M |
| Common Stock Direct | 9/13/2023 | F · Tax Withholding | −184.74K | $2.13 | $393.50K | 7.1% | 2.60M | 2.41M |
| Total | −212.66K | -$456.80K | ||||||
Derivative Transactions0
No derivative transactions reported